• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Veracyte, Inc. - Common Stock (NQ:VCYT)

    42.39 +0.29 (+0.69%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 493,045
    Open 42.14
    Bid (Size) 37.00 (100)
    Ask (Size) 46.00 (100)
    Prev. Close 42.10
    Today's Range 41.48 - 42.77
    52wk Range 22.61 - 50.71
    Shares Outstanding 67,473,870
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Inc (NASDAQ:VCYT) Emerges as a Top Affordable Growth Stock ↗
    Veracyte (VCYT) exemplifies the GARP strategy, offering strong growth, a reasonable industry price, and a solid debt-free financial foundation. 
    Via Chartmill

    Performance

    YTD
    N/A
    N/A
    1 Month
    -8.2%
    -8.2%
    3 Month
    +19.0%
    +19.0%
    6 Month
    +54.1%
    +54.1%
    1 Year
    +4.8%
    +4.8%

    More News

    Read More
    News headline image
    Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price ↗
    Via Chartmill
    News headline image
    Veracyte to Participate in Upcoming Investor Conferences
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 6, 2025 ↗
    Via Benzinga
    News headline image
    Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Veracyte Announces Third Quarter 2025 Financial Results
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech ↗
    Via Chartmill
    News headline image
    Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity ↗
    Via Chartmill
    News headline image
    Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Cancer Diagnostics ↗
    Via Chartmill
    News headline image
    Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential ↗
    Via Chartmill
    News headline image
    Veracyte (VCYT) Q2 Revenue Jumps 14% ↗
    Via The Motley Fool
    News headline image
    Veracyte Announces Second Quarter 2025 Financial Results
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics ↗
    Via Benzinga
    News headline image
    VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals ↗
    Via Chartmill

    Frequently Asked Questions

    Is Veracyte, Inc. - Common Stock publicly traded?
    Yes, Veracyte, Inc. - Common Stock is publicly traded.
    What exchange does Veracyte, Inc. - Common Stock trade on?
    Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Veracyte, Inc. - Common Stock?
    The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
    What is the current price of Veracyte, Inc. - Common Stock?
    The current price of Veracyte, Inc. - Common Stock is 42.39
    When was Veracyte, Inc. - Common Stock last traded?
    The last trade of Veracyte, Inc. - Common Stock was at 01/02/26 04:00 PM ET
    What is the market capitalization of Veracyte, Inc. - Common Stock?
    The market capitalization of Veracyte, Inc. - Common Stock is 2.86B
    How many shares of Veracyte, Inc. - Common Stock are outstanding?
    Veracyte, Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.